This article lays out the rationale and overall design of a new discussion site about quantitative methods.
Publications
Views expressed here are neither those of Vanderbilt University nor the US FDA
PhD in Biostatistics, 1979
UNC Chapel Hill
BS in Mathematics, 1973
University of Alabama Birmingham
This article lays out the rationale and overall design of a new discussion site about quantitative methods.
This article provides my reflections after the PCORI/PACE Evidence and the Individual Patient meeting on 2018-05-31. The discussion includes a high-level view of heterogeneity of treatment effect in optimizing treatment for individual patients.
This article elaborates on Frank Harrell’s post providing guidance in choosing between machine learning and statistical modeling for a prediction project.
This article provides general guidance to help researchers choose between machine learning and statistical modeling for a prediction project.
This article discusses issues related to alpha spending, effect sizes used in power calculations, multiple endpoints in RCTs, and endpoint labeling. Changes in endpoint priority is addressed. Included in the the discussion is how Bayesian probabilities more naturally allow one to answer multiple questions without all-too-arbitrary designations of endpoints as “primary” and “secondary”. And we should not quit trying to learn.
Enhancing capabilities of CDER and its Office of Biostatistics in Bayesian clinical trial design and analysis
I teach the BIOS7330 Regression Modeling Strategies course in the Biostatistics Graduate Program at Vanderbilt University in the spring semester. The course web page is here. I teach a 4-day version of this course each May at Vanderbilt. Registration information for the short course may be found here.
stackexchangevanderbilt.edu,
otherwise you can make a request to join)